Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.34 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5595684 | 0.79 | LPAR1 (0.38) | MEN1KMT2A | |
| SCHEMBL8321854 | 0.78 | TACR1 (0.47) | MEN1KMT2AHPGDKDM4CCACNA1B | |
| SCHEMBL3506600 | 0.77 | KDM4C (0.42) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL14538695 | 0.76 | NPC1 (0.44) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL22653145 | 0.75 | KDM4C (0.41) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL22633364 | 0.75 | KDM4C (0.41) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL2354473 | 0.74 | MEN1 (0.41) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL19067485 | 0.72 | MEN1 (0.36) | MEN1KMT2AKDM4C | |
| SCHEMBL27031868 | 0.70 | KDM4C (0.41) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL27032269 | 0.70 | KDM4C (0.41) | MEN1KMT2AKDM4CNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123492-A1 | Analogs of lysophosphatidic acid and methods of making and using thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123492-A1 | Analogs of lysophosphatidic acid and methods of making and using thereof | LPAR4, LPAR2, LPAR5 | MEN1 758/4885KMT2A 1248/4885HPGD 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.